Myeloma

A study to determine the effect and safety of an oral Janus kinase 2 (JAK2)-inhibitor (Ruxolitinib; INBC018424) in patients with multiple myeloma

Incyte Study ID:
INCB 18424-255
CT.gov ID:
NCT00639002
View Results Summary
Eudra ID:
N/A
Sponsor:
Incyte Corporation
Collaborator:
N/A
Study Contact Information:
1.855.463.3463
Study Complete
Subscribe to UpdatesContact Us

Clinical Study Purpose

The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.

Clinical Study Summary

MEDICAL CONDITION(S)
  • Myeloma
    • PRODUCT
  • Drug: Ruxolitinib 25 mg
  • Drug: Dexamethasone 40 mg
    • COLLABORATORS
    N/A
    DATE
    Mar 2008 - Jul 2010
    TYPE
    Interventional
    PHASE
    Phase 2
    SEX
    Female & Male
    AGE
    18+ years
    ACCEPTS HEALTHY VOLUNTEERS
    No

    Clinical Study Locations

    Name
    Contact Us
    Name
    New York, New York, US, 10011
    Name
    Highland, California, US, 92346
    Name
    Boynton Beach, Florida, US, 33435

    Key Inclusion and Exclusion Criteria

    Inclusion Criteria

    • Confirmed diagnosis of multiple myeloma with evidence of measurable disease.
    • Relapsed or refractory disease with at least one line of prior therapy.

    Exclusion Criteria

    • Received anti-cancer medications or investigational therapy in the past 28 days.
    • Intracranial disease or epidural disease.

    Protocol Summary

    Incyte Study ID:
    INCB 18424-255
    Primary Purpose:
    Treatment
    Allocation:
    N/A
    Study Design:
    Single Group Assignment
    Masking:
    None (Open Label)
    Interventions:
    Drug
    Enrollment:
    13
    Primary Outcome
    Open
    Secondary Outcome
    Open